Mirum Pharmaceuticals (MIRM) Competitors $46.08 -0.20 (-0.43%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$46.16 +0.08 (+0.17%) As of 03/27/2025 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MIRM vs. QGEN, ROIV, SRPT, RVMD, BBIO, LNTH, TGTX, LEGN, AXSM, and TLXShould you be buying Mirum Pharmaceuticals stock or one of its competitors? The main competitors of Mirum Pharmaceuticals include Qiagen (QGEN), Roivant Sciences (ROIV), Sarepta Therapeutics (SRPT), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), Lantheus (LNTH), TG Therapeutics (TGTX), Legend Biotech (LEGN), Axsome Therapeutics (AXSM), and Telix Pharmaceuticals Limited American Depositary Shares (TLX). These companies are all part of the "pharmaceutical products" industry. Mirum Pharmaceuticals vs. Qiagen Roivant Sciences Sarepta Therapeutics Revolution Medicines BridgeBio Pharma Lantheus TG Therapeutics Legend Biotech Axsome Therapeutics Telix Pharmaceuticals Limited American Depositary Shares Qiagen (NYSE:QGEN) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, community ranking, dividends, media sentiment, institutional ownership, analyst recommendations and profitability. Do insiders & institutionals believe in QGEN or MIRM? 70.0% of Qiagen shares are owned by institutional investors. 9.0% of Qiagen shares are owned by insiders. Comparatively, 22.9% of Mirum Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community believe in QGEN or MIRM? Qiagen received 117 more outperform votes than Mirum Pharmaceuticals when rated by MarketBeat users. However, 75.86% of users gave Mirum Pharmaceuticals an outperform vote while only 60.29% of users gave Qiagen an outperform vote. CompanyUnderperformOutperformQiagenOutperform Votes24960.29% Underperform Votes16439.71% Mirum PharmaceuticalsOutperform Votes13275.86% Underperform Votes4224.14% Which has stronger earnings & valuation, QGEN or MIRM? Qiagen has higher revenue and earnings than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQiagen$1.98B4.45$83.59M$0.36110.14Mirum Pharmaceuticals$336.89M6.70-$163.41M-$1.85-24.91 Is QGEN or MIRM more profitable? Qiagen has a net margin of 4.23% compared to Mirum Pharmaceuticals' net margin of -31.69%. Qiagen's return on equity of 13.92% beat Mirum Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Qiagen4.23% 13.92% 8.40% Mirum Pharmaceuticals -31.69%-41.22%-14.81% Does the media favor QGEN or MIRM? In the previous week, Mirum Pharmaceuticals had 2 more articles in the media than Qiagen. MarketBeat recorded 6 mentions for Mirum Pharmaceuticals and 4 mentions for Qiagen. Mirum Pharmaceuticals' average media sentiment score of 0.97 beat Qiagen's score of 0.26 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mirum Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate QGEN or MIRM? Qiagen currently has a consensus target price of $47.71, indicating a potential upside of 20.32%. Mirum Pharmaceuticals has a consensus target price of $58.20, indicating a potential upside of 26.30%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Mirum Pharmaceuticals is more favorable than Qiagen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qiagen 0 Sell rating(s) 7 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.30Mirum Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09 Which has more risk & volatility, QGEN or MIRM? Qiagen has a beta of 0.44, meaning that its stock price is 56% less volatile than the S&P 500. Comparatively, Mirum Pharmaceuticals has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500. SummaryMirum Pharmaceuticals beats Qiagen on 10 of the 19 factors compared between the two stocks. Remove Ads Get Mirum Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIRM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MIRM vs. The Competition Export to ExcelMetricMirum PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.26B$6.92B$5.65B$8.06BDividend YieldN/A2.72%4.57%4.01%P/E Ratio-22.817.2023.1719.03Price / Sales6.70226.01385.1993.17Price / CashN/A65.6738.1634.64Price / Book8.656.476.944.33Net Income-$163.41M$141.90M$3.20B$247.06M7 Day Performance-2.00%-3.20%-2.29%-0.37%1 Month Performance-3.13%-5.64%2.88%-3.85%1 Year Performance83.44%-7.47%10.82%1.27% Mirum Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MIRMMirum Pharmaceuticals4.3904 of 5 stars$46.08-0.4%$58.20+26.3%+83.4%$2.26B$336.89M-22.81140QGENQiagen3.5121 of 5 stars$39.87+0.5%$47.71+19.7%-4.6%$8.85B$1.98B111.026,030Short Interest ↑ROIVRoivant Sciences2.2086 of 5 stars$10.83+0.4%$18.08+67.0%-3.3%$7.73B$122.59M-72.20860SRPTSarepta Therapeutics4.8422 of 5 stars$76.33+3.0%$167.41+119.3%-44.9%$7.41B$1.90B61.061,314Gap UpRVMDRevolution Medicines4.1616 of 5 stars$39.34+3.2%$66.31+68.6%+20.1%$7.31B$742,000.00-10.96250Positive NewsBBIOBridgeBio Pharma4.6261 of 5 stars$37.22+7.0%$52.90+42.1%+18.0%$7.08B$221.90M-13.06400Insider TradeHigh Trading VolumeLNTHLantheus4.2972 of 5 stars$99.44+1.8%$129.43+30.2%+60.5%$6.81B$1.53B16.55700TGTXTG Therapeutics3.0867 of 5 stars$42.61-0.9%$40.67-4.6%+158.2%$6.69B$329.00M-426.06290Positive NewsLEGNLegend Biotech2.8876 of 5 stars$36.33-1.7%$79.00+117.5%-37.8%$6.67B$627.24M-38.241,800Short Interest ↓Positive NewsAXSMAxsome Therapeutics4.7721 of 5 stars$129.17+1.9%$167.36+29.6%+53.8%$6.30B$385.69M-21.56380Analyst ForecastShort Interest ↓TLXTelix Pharmaceuticals Limited American Depositary SharesN/A$18.24+2.5%$22.00+20.6%N/A$6.14B$783.21M0.00N/AGap Up Remove Ads Related Companies and Tools Related Companies Qiagen Competitors Roivant Sciences Competitors Sarepta Therapeutics Competitors Revolution Medicines Competitors BridgeBio Pharma Competitors Lantheus Competitors TG Therapeutics Competitors Legend Biotech Competitors Axsome Therapeutics Competitors Telix Pharmaceuticals Limited American Depositary Shares Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MIRM) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mirum Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mirum Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MIRM Stock Free MIRM Stock Alerts